240 related articles for article (PubMed ID: 37716332)
21. Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
Varnai R; Sipeky C
Pharmacogenomics; 2020 Oct; 21(15):1101-1115. PubMed ID: 33021139
[TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
23. PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
Bieńkowski M; Tomasik B; Braun M; Jassem J
Cancer Treat Rev; 2022 Mar; 104():102359. PubMed ID: 35190335
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
Zhang M; Yu X; Wang J; Li Y; Cao L
J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
[TBL] [Abstract][Full Text] [Related]
25. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
[TBL] [Abstract][Full Text] [Related]
26. Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence.
Yang J; Xiong X; Zheng W; Liao X; Xu H; Yang L; Wei Q
Curr Oncol; 2023 Dec; 30(12):10311-10324. PubMed ID: 38132385
[TBL] [Abstract][Full Text] [Related]
27. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis.
Chang XF; Ren XL; Yang JQ; Shi JJ; Bai JH; Cui MS; Dong WW
Breast; 2021 Oct; 59():44-50. PubMed ID: 34130011
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Sokolova AO; Marshall CH; Lozano R; Gulati R; Ledet EM; De Sarkar N; Grivas P; Higano CS; Montgomery B; Nelson PS; Olmos D; Sokolov V; Schweizer MT; Yezefski TA; Yu EY; Paller CJ; Sartor O; Castro E; Antonarakis ES; Cheng HH
Prostate; 2021 Dec; 81(16):1382-1389. PubMed ID: 34516663
[TBL] [Abstract][Full Text] [Related]
30. Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out?
Higano CS; Cheng HH
Curr Opin Urol; 2023 Sep; 33(5):396-403. PubMed ID: 37497748
[TBL] [Abstract][Full Text] [Related]
31. Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in
Chakraborty G; Patail NK; Hirani R; Nandakumar S; Mazzu YZ; Yoshikawa Y; Atiq M; Jehane LE; Stopsack KH; Lee GM; Abida W; Morris MJ; Mucci LA; Danila D; Kantoff PW
Clin Cancer Res; 2021 Mar; 27(6):1792-1806. PubMed ID: 33334906
[TBL] [Abstract][Full Text] [Related]
32. The emerging role of PARP inhibitors in prostate cancer.
Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
[TBL] [Abstract][Full Text] [Related]
33. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Slootbeek PHJ; Duizer ML; van der Doelen MJ; Kloots ISH; Kuppen MCP; Westgeest HM; Uyl-de Groot CA; Pamidimarri Naga S; Ligtenberg MJL; van Oort IM; Gerritsen WR; Schalken JA; Kroeze LI; Bloemendal HJ; Mehra N
Int J Cancer; 2021 Jan; 148(2):385-395. PubMed ID: 32965028
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Wu K; Liang J; Shao Y; Xiong S; Feng S; Li X
Front Pharmacol; 2021; 12():777663. PubMed ID: 34975480
[No Abstract] [Full Text] [Related]
35. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Abida W; Campbell D; Patnaik A; Bryce AH; Shapiro J; Bambury RM; Zhang J; Burke JM; Castellano D; Font A; Ganju V; Hardy-Bessard AC; McDermott R; Sautois B; Spaeth D; Voog E; Piulats JM; Pintus E; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Loehr A; Despain D; Simmons AD; Dowson M; Go J; Watkins SP; Chowdhury S
Eur Urol; 2023 Sep; 84(3):321-330. PubMed ID: 37277275
[TBL] [Abstract][Full Text] [Related]
36. Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
Maiorano BA; De Giorgi U; Verzoni E; Maiello E; Procopio G; Conteduca V; Di Maio M;
Target Oncol; 2024 Jan; 19(1):1-11. PubMed ID: 37993604
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis.
Hong X; Zhang Y; Chi Z; Xu Q; Lin W; Huang Y; Lin T; Zhang Y
Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):e20-e30. PubMed ID: 37993317
[TBL] [Abstract][Full Text] [Related]
38. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
39. Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells.
Uddin MH; Li Y; Khan HY; Muqbil I; Aboukameel A; Sexton RE; Reddy S; Landesman Y; Kashyap T; Azmi AS; Heath EI
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206543
[TBL] [Abstract][Full Text] [Related]
40. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]